Department of Physiology, School of Medicine, Jiangsu University, No. 301 Xuefu Road, Zhenjiang, Jiangsu 212013, People's Republic of China; Department of Applied Biology, University for Development Studies, Navrongo, Ghana.
Department of Physiology, School of Medicine, Jiangsu University, No. 301 Xuefu Road, Zhenjiang, Jiangsu 212013, People's Republic of China.
Crit Rev Oncol Hematol. 2017 Jan;109:20-34. doi: 10.1016/j.critrevonc.2016.11.008. Epub 2016 Nov 21.
To investigate oncogenic platelet-derived growth factor receptor(PDGFR) fusion genes involvement in hematological malignancies, the advances in the PDGFR fusion genes diagnosis and development of PDGFR fusions inhibitors.
Literature search was done using terms "PDGFR and Fusion" or "PDGFR and Myeloid neoplasm" or 'PDGFR and Lymphoid neoplasm' or "PDGFR Fusion Diagnosis" or "PDGFR Fusion Targets" in databases including PubMed, ASCO.org, and Medscape.
Out of the 36 fusions detected, ETV6(TEL)-PDGFRB and FIP1L1-PDGFRA fusions were frequently detected, 33 are as a result of chromosomal translocation, FIP1L1-PDGFRA and EBF1-PDGFRB are the result of chromosomal deletion and CDK5RAP2- PDGFRΑ is the result of chromosomal insertion. Seven of the 34 rare fusions have detectable reciprocals.
RNA aptamers are promising therapeutic target of PDGFRs and diagnostic tools of PDGFRs fusion genes. Also, PDGFRs have variable prospective therapeutic strategies including small molecules, RNA aptamers, and interference therapeutics as well as development of adaptor protein Lnk mimetic drugs.
研究致癌性血小板衍生生长因子受体（PDGFR）融合基因在血液系统恶性肿瘤中的作用，探讨 PDGFR 融合基因诊断的进展和 PDGFR 融合抑制剂的开发。
通过在 PubMed、ASCO.org 和 Medscape 等数据库中使用术语“PDGFR 和融合”或“PDGFR 和髓系肿瘤”或“PDGFR 和淋巴肿瘤”或“PDGFR 融合诊断”或“PDGFR 融合靶点”进行文献检索。
在检测到的 36 种融合中，ETV6（TEL）-PDGFRB 和 FIP1L1-PDGFRA 融合较为常见，其中 33 种是染色体易位的结果，FIP1L1-PDGFRA 和 EBF1-PDGFRB 是染色体缺失的结果，CDK5RAP2-PDGFRΑ 是染色体插入的结果。34 种罕见融合中有 7 种可检测到相互对应的融合。
RNA 适体是 PDGFRs 的有前途的治疗靶点和 PDGFRs 融合基因的诊断工具。此外，PDGFRs 具有多种潜在的治疗策略，包括小分子、RNA 适体和干扰治疗，以及开发衔接蛋白 Lnk 模拟药物。
